Back

TREM2 limits necrotic core formation during atherogenesis by controlling macrophage survival and efferocytosis

Piollet, M.; Porsch, F.; Rizzo, G.; Kapser, F.; Schulz, D. J.; Kiss, M. G.; Schlepckow, K.; Morenas-Rodriguez, E.; Sen, M. O.; Gropper, J.; Roesch, M.; Goederle, L.; Hladik, A.; Knapp, S.; Colonna, M.; Martini, R.; Haass, C.; Zernecke, A.; Binder, C. J.; Cochain, C.

2023-05-15 immunology
10.1101/2023.05.15.539977 bioRxiv
Show abstract

Atherosclerosis is a chronic disease of the vascular wall driven by lipid accumulation and inflammation in the intimal layer of arteries [1], [2], and its main complications, myocardial infarction and stroke, are the leading cause of mortality worldwide [3]. Recent studies have identified Triggering receptor expressed on myeloid cells 2 (TREM2), a lipid-sensing receptor regulating several key myeloid cell functions [4], as a highly expressed marker of macrophage foam cells in experimental and human atherosclerosis [5]. However, the function of TREM2 in the development of atherosclerosis is unknown. Here, we show that hematopoietic or global TREM2 deficiency increases necrotic core formation in early experimental atherosclerosis. We further demonstrate that TREM2 is essential for the efferocytosis capacities of macrophages, and to the survival of lipid-laden macrophages, altogether indicating a crucial role of TREM2 in maintaining the balance between foam cell death and their clearance in atherosclerotic lesions, thereby controlling plaque necrosis.

Matching journals

The top 3 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.